About this data
What it is
The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
Who files it
The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
How current
We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
Terms
openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
Worth knowing
This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
Not to be confused with
Clinical trial updates: what sponsors report about their studies, not what the FDA decided.

All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.

FDA decisions per day, last 30 days

010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0
010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0

Brand-name drugs and biologics, with supplements Device clearances and approvals

By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.

Latest FDA decisions

Reset

Showing: ticker GSK · Everything

Latest FDA decisions
DecidedProductApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.FDA page
Oct 30, 2026BENLYSTA
BELIMUMAB
GSK
Glaxosmithkline LLC
Biologic (BLA), supplement
Labeling
BLA761043 ↗
Letter or label ↗
Oct 20, 2026HIBSAGO
BEPIROVIRSEN
GSK
Glaxosmithkline LLC
New drug (NDA)
Type 1 - New Molecular Entity
NDA221276 ↗
Oct 19, 2026JEMPERLI
DOSTARLIMAB-GXLY
GSK
Glaxosmithkline
Biologic (BLA), supplement
Efficacy
BLA761174 ↗
Aug 21, 2026BENLYSTA
BELIMUMAB
GSK
Glaxosmithkline LLC
Biologic (BLA), supplement
Labeling
BLA761043 ↗
Jul 24, 2026BREXAFEMME
IBREXAFUNGERP CITRATE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA214900 ↗
Jul 20, 2026OJJAARA
MOMELOTINIB DIHYDROCHLORIDE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA216873 ↗
Jun 17, 2026UTEBZI
TEBIPENEM PIVOXIL HYDROBROMIDE
GSK
Glaxosmithkline
New drug (NDA)
Type 1 - New Molecular Entity
NDA215960 ↗
Jun 10, 2026MALARONE
ATOVAQUONE; PROGUANIL HYDROCHLORIDE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA021078 ↗
Jun 10, 2026EXDENSUR
DEPEMOKIMAB-ULAA
GSK
Glaxosmithkline LLC
Biologic (BLA), supplement
Labeling
BLA761458 ↗
Mar 27, 2026ZEJULA
NIRAPARIB TOSYLATE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA214876 ↗
Mar 23, 2026MALARONE
ATOVAQUONE; PROGUANIL HYDROCHLORIDE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA021078 ↗
Mar 20, 2026MEPRON
ATOVAQUONE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA020500 ↗
Mar 18, 2026OJJAARA
MOMELOTINIB DIHYDROCHLORIDE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA216873 ↗
Mar 18, 2026OJJAARA
MOMELOTINIB DIHYDROCHLORIDE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA216873 ↗
Mar 9, 2026WELLCOVORIN
LEUCOVORIN CALCIUM
GSK
Glaxosmithkline
New drug (NDA), supplement
Efficacy
NDA018342 ↗
Dec 16, 2025EXDENSUR
DEPEMOKIMAB-ULAA
GSK
Glaxosmithkline LLC
Biologic (BLA)
Type 1 - New Molecular Entity
BLA761458 ↗
Dec 11, 2025BLUJEPA
GEPOTIDACIN MESYLATE
GSK
Glaxosmithkline
New drug (NDA), supplement
Efficacy
NDA218230 ↗
Dec 9, 2025SUMATRIPTAN
SUMATRIPTAN
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA020626 ↗
Dec 9, 2025IMITREX
SUMATRIPTAN SUCCINATE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA020132 ↗
Dec 9, 2025IMITREX
SUMATRIPTAN SUCCINATE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA020080 ↗
Nov 12, 2025VALTREX
VALACYCLOVIR HYDROCHLORIDE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA020487 ↗
Nov 5, 2025WELLBUTRIN SR
BUPROPION HYDROCHLORIDE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA020358 ↗
Nov 5, 2025WELLBUTRIN
BUPROPION HYDROCHLORIDE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA018644 ↗
Nov 3, 2025BREXAFEMME
IBREXAFUNGERP CITRATE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA214900 ↗
Oct 23, 2025BLENREP
BELANTAMAB MAFODOTIN-BLMF
GSK
Glaxosmithkline LLC
Biologic (BLA)
Type 2 - New Active Ingredient
BLA761440 ↗
Oct 10, 2025LAMICTAL ODT
LAMOTRIGINE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA022251 ↗
Oct 10, 2025LAMICTAL ODT
LAMOTRIGINE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA022251 ↗
Oct 10, 2025LAMICTAL XR
LAMOTRIGINE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA022115 ↗
Oct 10, 2025LAMICTAL XR
LAMOTRIGINE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA022115 ↗
Oct 10, 2025LAMICTAL
LAMOTRIGINE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA020764 ↗
Oct 10, 2025LAMICTAL
LAMOTRIGINE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA020764 ↗
Oct 10, 2025LAMICTAL
LAMOTRIGINE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA020241 ↗
Letter or label ↗
Oct 10, 2025LAMICTAL
LAMOTRIGINE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA020241 ↗
Aug 6, 2025NUCALA
MEPOLIZUMAB
GSK
Glaxosmithkline
Biologic (BLA), supplement
Labeling
BLA761122 ↗
Jul 18, 2025ZEJULA
NIRAPARIB TOSYLATE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA214876 ↗
Jun 20, 2025BENLYSTA
BELIMUMAB
GSK
Glaxosmithkline LLC
Biologic (BLA), supplement
Efficacy
BLA761043 ↗
Jun 18, 2025ZEJULA
NIRAPARIB TOSYLATE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA214876 ↗
Jun 18, 2025ZEJULA
NIRAPARIB TOSYLATE
GSK
Glaxosmithkline
New drug (NDA), supplement
Efficacy
NDA214876 ↗
May 22, 2025NUCALA
MEPOLIZUMAB
GSK
Glaxosmithkline LLC
Biologic (BLA), supplement
Efficacy
BLA125526 ↗
Apr 25, 2025LAMICTAL ODT
LAMOTRIGINE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA022251 ↗
Letter or label ↗
Apr 25, 2025LAMICTAL ODT
LAMOTRIGINE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA022251 ↗
Letter or label ↗
Apr 25, 2025LAMICTAL XR
LAMOTRIGINE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA022115 ↗
Letter or label ↗
Apr 25, 2025LAMICTAL XR
LAMOTRIGINE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA022115 ↗
Letter or label ↗
Apr 25, 2025LAMICTAL
LAMOTRIGINE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA020764 ↗
Letter or label ↗
Apr 25, 2025LAMICTAL
LAMOTRIGINE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA020764 ↗
Letter or label ↗
Apr 25, 2025LAMICTAL
LAMOTRIGINE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA020241 ↗
Letter or label ↗
Apr 25, 2025LAMICTAL
LAMOTRIGINE
GSK
Glaxosmithkline LLC
New drug (NDA), supplement
Labeling
NDA020241 ↗
Letter or label ↗
Apr 18, 2025OJJAARA
MOMELOTINIB DIHYDROCHLORIDE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA216873 ↗
Letter or label ↗
Mar 25, 2025BLUJEPA
GEPOTIDACIN MESYLATE
GSK
Glaxosmithkline
New drug (NDA)
Type 1 - New Molecular Entity
NDA218230 ↗
Feb 5, 2025WELLBUTRIN
BUPROPION HYDROCHLORIDE
GSK
Glaxosmithkline
New drug (NDA), supplement
Labeling
NDA018644 ↗

The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:31 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates